Clinical Trial Results - Progress in Cancer Care
These summaries highlight recently released results from cancer clinical trials. The findings are significant enough that they are likely to influence your medical care.
The summaries are listed in reverse chronological order. You may also use the navigation tools on the left to search the summaries by keyword or type of cancer.
Chemotherapy Combination Improves Survival in Elderly Lung Cancer Patients
(Posted: 06/23/2010, Updated: 09/06/2011) - Survival can be improved in older patients with advanced non-small cell lung cancer (NSCLC) with the use of two chemotherapy drugs as opposed to a single agent.
Cetuximab Combined with Oxaliplatin-Based Chemotherapy May Not Be Effective First-Line Treatment for Metastatic Colorectal Cancer
(Posted: 08/30/2011) - In a randomized phase III trial, the addition of the targeted therapy cetuximab to oxaliplatin and fluoropyrimidine chemotherapy did not prolong survival or time to disease progression of patients with advanced colorectal cancer. The results were published on June 5, 2011 in The Lancet.
Ovarian Cancer Screening Method Fails to Reduce Deaths from the Disease
(Posted: 07/27/2011) - New results from the NCI-sponsored Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial show that screening for ovarian cancer with transvaginal ultrasound (TVU) and the CA-125 blood test did not result in fewer deaths from the disease compared with usual care.
NIH-funded study shows reduction in death for men with intermediate-grade prostate cancer:
(Posted: 07/13/2011) - Short-term hormone therapy given in combination with radiation therapy to men with early-stage prostate cancer increased their chances of living longer compared to treatment with radiation therapy alone, according to a clinical trial supported by NCI. Benefits of the combined treatment were limited mainly to patients with intermediate-risk disease and were not seen for men with low-risk prostate cancer, researchers say.
Colorectal Cancer Trials Support Gene Testing for Two Drugs
(Posted: 11/12/2008, Updated: 07/08/2011) - A trio of 2008 studies adds to the growing evidence that patients with colorectal cancer should have their tumors tested for genetic mutations prior to starting therapy with cetuximab (Erbitux®) or panitumumab (Vectibix®).
(Posted: 06/23/2010, Updated: 09/06/2011) - Survival can be improved in older patients with advanced non-small cell lung cancer (NSCLC) with the use of two chemotherapy drugs as opposed to a single agent.
Cetuximab Combined with Oxaliplatin-Based Chemotherapy May Not Be Effective First-Line Treatment for Metastatic Colorectal Cancer
(Posted: 08/30/2011) - In a randomized phase III trial, the addition of the targeted therapy cetuximab to oxaliplatin and fluoropyrimidine chemotherapy did not prolong survival or time to disease progression of patients with advanced colorectal cancer. The results were published on June 5, 2011 in The Lancet.
Ovarian Cancer Screening Method Fails to Reduce Deaths from the Disease
(Posted: 07/27/2011) - New results from the NCI-sponsored Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial show that screening for ovarian cancer with transvaginal ultrasound (TVU) and the CA-125 blood test did not result in fewer deaths from the disease compared with usual care.
NIH-funded study shows reduction in death for men with intermediate-grade prostate cancer:
(Posted: 07/13/2011) - Short-term hormone therapy given in combination with radiation therapy to men with early-stage prostate cancer increased their chances of living longer compared to treatment with radiation therapy alone, according to a clinical trial supported by NCI. Benefits of the combined treatment were limited mainly to patients with intermediate-risk disease and were not seen for men with low-risk prostate cancer, researchers say.
Colorectal Cancer Trials Support Gene Testing for Two Drugs
(Posted: 11/12/2008, Updated: 07/08/2011) - A trio of 2008 studies adds to the growing evidence that patients with colorectal cancer should have their tumors tested for genetic mutations prior to starting therapy with cetuximab (Erbitux®) or panitumumab (Vectibix®).
